Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Total Valuation
Genmab has a market cap or net worth of $17.90B. The enterprise value is $15.77B.
Market Cap$17.90B
Enterprise Value$15.77B
Share Statistics
Genmab has 642,063,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding642,063,500
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 14.13%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)14.13%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee8.16M
Profits Per Employee2.97M
Employee Count2,638
Asset Turnover0.47
Inventory Turnover15.89
Valuation Ratios
The current PE Ratio of Genmab is 12.8. Genmab’s PEG ratio is 0.15.
PE Ratio12.8
PS Ratio4.51
PB Ratio2.65
Price to Fair Value2.65
Price to FCF12.81
Price to Operating Cash Flow17.13
PEG Ratio0.15
Income Statement
In the last 12 months, Genmab had revenue of 21.53B and earned 7.84B in profits. Earnings per share was 12.14.
Revenue21.53B
Gross Profit20.54B
Operating Income6.70B
Pretax Income9.16B
Net Income7.84B
EBITDA9.70B
Earnings Per Share (EPS)12.14
Cash Flow
In the last 12 months, operating cash flow was 5.59B and capital expenditures -363.20M, giving a free cash flow of 5.23B billion.
Operating Cash Flow5.59B
Free Cash Flow5.23B
Free Cash Flow per Share8.14
Dividends & Yields
Genmab pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change43.86%
50-Day Moving Average29.85
200-Day Moving Average23.41
Relative Strength Index (RSI)57.39
Average Volume (3m)2.77M
Important Dates
Genmab upcoming earnings date is Feb 25, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Genmab as a current ratio of 5.25, with Debt / Equity ratio of 2.79%
Current Ratio5.25
Quick Ratio5.24
Debt to Market Cap0.00
Net Debt to EBITDA-0.91
Interest Coverage Ratio55.86
Taxes
In the past 12 months, Genmab has paid 1.32B in taxes.
Income Tax1.32B
Effective Tax Rate0.14
Enterprise Valuation
Genmab EV to EBITDA ratio is 9.11, with an EV/FCF ratio of 11.65.
EV to Sales4.10
EV to EBITDA9.11
EV to Free Cash Flow11.65
EV to Operating Cash Flow11.37
Balance Sheet
Genmab has $3.41B in cash and marketable securities with $142.00M in debt, giving a net cash position of $3.27B billion.
Cash & Marketable Securities$3.41B
Total Debt$142.00M
Net Cash$3.27B
Net Cash Per Share$5.09
Tangible Book Value Per Share$33.76
Margins
Gross margin is 94.46%, with operating margin of 31.14%, and net profit margin of 36.44%.
Gross Margin94.46%
Operating Margin31.14%
Pretax Margin42.57%
Net Profit Margin36.44%
EBITDA Margin45.05%
EBIT Margin43.13%
Analyst Forecast
The average price target for Genmab is $41.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.00
Price Target Upside34.56% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast24.98%
EPS Growth Forecast127.06%